Bluebird’s Zynteglo Launch Under Way, But First Revenue Will Take Months
First Sales Of Newly Approved Product Expected In Q1 2023
Bluebird bio will not see revenue for Zynteglo until it is infused into beta-thalassemia patients, which will take months due to the ex vivo gene therapy’s complex manufacturing and quality control process.
